Abstract

High density peptide microarray technologies can be applied in experimental medicine in general and in clinical immunology in particular. Laboratory diagnostics of autoimmune diseases strongly rely on screening human sera for antibodies against known autoantigens. These assays are still difficult to standardize and quantify. Typically, the results are presented as antibody titers within an assay system. Most assays use recombinant or purified autoantigens that are difficult to obtain and require great efforts of quality control. Here we describe a method to obtain patterns of epitope signatures with peptide microarrays from patients suffering from autoimmune diseases in comparison with healthy controls. One of the final aims will be to define subsets of peptides indicative for marker autoantibodies of autoimmune diseases. Finally, informative epitopes can be used for immunopurifying epitope-specific autoantibodies. Eventually, these antibodies can be further characterized on peptide microarrays displaying mutated epitopes obtained by scanning mutagenesis. Any disease or physiological status that affect humoral immune responses such as autoantibodies in oncology or responses to infections or vaccinations can be monitored.